Physician profile
Sanjay Lall
NPI 1699779488
$1,083.06
in general payments reported to CMS, 2019-2025
15 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $103 · 2021: $94.82 · 2022: $154 · 2023: $247 · 2024: $111 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $201.88 | 2020-2024 | |
| Edwards Lifesciences Corporation | $142.14 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $125.11 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $116.33 | 2020-2025 | Watchman Flx |
| Pfizer INC. | $88.13 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.61 | 2019-2022 | |
| Ionis Pharmaceuticals, INC. | $52.19 | 2025 | Tryngolza |
| E.R. Squibb & Sons, L.L.C. | $50.29 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.78 | 2023 | Lifevest |
| Esperion Therapeutics, INC. | $46.83 | 2020-2025 | Nexletol |
| Heartflow, INC. | $40.38 | 2022-2025 | |
| Cvrx, INC. | $39.30 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $21.68 | 2023 | Xarelto |
| Amarin Pharma, INC. | $17.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.20 | 2024 | Evkeeza, Praluent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Lall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.